Why Non-Diabetics Are Wearing Glucose Monitors (and Whether the Data Is Worth It)

It starts with a banana. Someone wears a continuous glucose monitor for a week, sees their blood sugar spike after eating it, and concludes they should stop eating fruit. The spike looked dramatic on the app. The data seemed undeniable. But for a person without diabetes, that reading may mean very little.

CGMs have been standard care in diabetes management for years. The technology uses a tiny sensor wire inserted under the skin to measure glucose in the interstitial fluid, generating a new reading every few minutes around the clock. What changed recently is availability. In March 2024, the FDA cleared Dexcom Stelo as the first over-the-counter CGM without a prescription requirement. Abbott Lingo received clearance in June 2024. Suddenly, anyone could buy one [2].

Why Non-Diabetics Are Buying Them

The appeal is easy to understand. The potential benefits promoted by CGM proponents include early detection of prediabetes, identification of food triggers, and optimization of athletic performance. Some users simply want to understand how their body responds to different meals. Others are curious about patterns they have never measured before. The devices pair with smartphone apps that display trends, graphs, and personalized insights [1].

The commercial angle is obvious. OTC CGMs cost $83-$99 per month out-of-pocket [2]. For roughly $1,000 per year, you get continuous data about your blood sugar. That price point has not slowed demand.

What the Research Actually Shows

A 2024 review of CGM studies found that receiving real-time glucose feedback reduced HbA1c by 0.3% and increased time in the normal glucose range by 7% [2]. These numbers sound meaningful until you look at who was studied. Most participants had prediabetes or other metabolic conditions. The evidence for healthy, non-diabetic users is much thinner.

In a study of 153 people without diabetes, blood sugar levels were within the normal range roughly 96% of the time [1]. A more recent study from Mass General Brigham examined 157 people without diabetes and found that the CGM frequently flagged values outside what the device defined as normal range. Those flagged readings were clinically meaningless. They resolved on their own without treatment or intervention [3]. The researchers recommended against routine CGM use in people without diabetes, noting that the devices are calibrated for diabetic physiology, not the physiology of someone whose glucose regulation works as intended.

The Accuracy Problem in Healthy People

This is where the mechanism matters. CGMs measure glucose in interstitial fluid, not blood. The relationship between the two is affected by factors including sensor calibration, lag time, and individual physiology. In people with diabetes, where glucose swings are large and clinically significant, these limitations are well understood and accounted for.

In someone without diabetes, the same device may flag a reading of 120 mg/dL after a meal as elevated. That number falls within the normal postprandial response for many people. But because the CGM is designed to alert diabetics to clinically significant excursions, a non-diabetic user sees a number that looks high and acts on it. Harvard physician Dr. Robert Shmerling put it directly: "just because you can measure something doesn't mean you should" [1].

The downstream effects can cut both ways. Some users respond to perceived spikes by eating less or changing food choices. Others report increased anxiety about eating when they see fluctuating numbers, or unnecessary snacking to correct what turns out to be normal physiological variation [1].

Who Might Still Benefit

This is not a uniform dismissal. There are scenarios where CGM data could be genuinely useful for someone without diabetes. A person with a strong family history of diabetes might catch an early pattern worth discussing with their doctor. Someone with unexplained symptoms that suggest glucose dysregulation could have a real condition revealed rather than hidden by the noise. Athletes seeking to understand recovery metrics might find the data actionable if they have a framework for interpreting it.

But these are specific cases. For the majority of healthy adults wearing CGMs to optimize their wellness routine, the evidence suggests the data is generating more noise than signal.

The Bottom Line

If you are considering an OTC CGM, the honest answer is that the cost is real and the health benefits for non-diabetics are not well established. No published study demonstrates that CGM monitoring improves health outcomes in people without diabetes [1]. The Mass General Brigham findings suggest the devices frequently flag clinically insignificant variation in healthy people, raising the risk of unnecessary concern or behavioral changes based on misleading readings [3].

The numbers look precise. The graphs look scientific. But a device built to track pathological glucose swings in diabetics may not give you meaningful information about your metabolic health. Before spending $1,000 a year on a wellness device, it is reasonable to ask whether the data will change anything you do, or whether you are paying for the feeling of optimization rather than the thing itself.